Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival.
FDG-PET-CT scan
checkpoint inhibitors
melanoma
outcome
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 May 2021
26 May 2021
Historique:
received:
30
03
2021
revised:
15
05
2021
accepted:
21
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Checkpoint inhibitors have revolutionized the treatment of patients with metastasized melanoma. However, it remains unclear when to stop treatment. We retrospectively analyzed 45 patients (median age 64 years; 58% male) with metastasized melanoma from 3 cancer centers that received checkpoint inhibitors and discontinued therapy due to either immune-related adverse events or patient decision after an (
Identifiants
pubmed: 34073477
pii: cancers13112616
doi: 10.3390/cancers13112616
pmc: PMC8198795
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Oncol. 2017 Dec 10;35(35):3924-3933
pubmed: 29023213
Genes Chromosomes Cancer. 2019 Jan;58(1):3-11
pubmed: 30230086
Genes Chromosomes Cancer. 2016 Jun;55(6):505-21
pubmed: 26917275
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
Cancer Immunol Immunother. 2019 May;68(5):813-822
pubmed: 30123922
Melanoma Res. 2017 Apr;27(2):168-170
pubmed: 28099369
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1932-1943
pubmed: 33336264
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):376-383
pubmed: 29124281
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Ann Oncol. 2015 Dec;26(12):2375-91
pubmed: 26371282
N Engl J Med. 2013 Jul 11;369(2):122-33
pubmed: 23724867
Ann Oncol. 2018 Oct 1;29(10):2115-2120
pubmed: 30137228
Oncotarget. 2015 Dec 8;6(39):42008-18
pubmed: 26524482
Lancet Oncol. 2019 Sep;20(9):1187-1189
pubmed: 31345625
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Eur J Cancer. 1999 Dec;35(13):1773-82
pubmed: 10673991
Crit Rev Oncog. 2016;21(1-2):141-54
pubmed: 27481010
J Clin Oncol. 2020 May 20;38(15):1655-1663
pubmed: 32053428
Ann Oncol. 2019 Jul 1;30(7):1154-1161
pubmed: 30923820
J Clin Oncol. 2018 Jun 10;36(17):1668-1674
pubmed: 29283791